Pericardial effusion
Keros Therapeutics Halts Pulmonary Hypertension Drug After Safety Issues, Cuts 45% of Workforce
Keros Therapeutics; cibotercept; pulmonary arterial hypertension; PAH; layoffs; pericardial effusion; drug development halt; cost savings; biotech sector
Keros Therapeutics Halts Higher Dose Arms in PAH Trial Due to Pericardial Effusion Concerns
Keros Therapeutics, TROPOS trial, pulmonary arterial hypertension (PAH), cibotercept (KER-012), pericardial effusion, clinical trial safety